Galmed Pharmaceuticals
GLMD
28 hedge funds and large institutions have $24.5M invested in Galmed Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 6
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.02% → 0.02% (+0%)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
28% less capital invested
Capital invested by funds: $34M → $24.5M (-$9.52M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$4.54M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.24M |
| 3 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$297K |
| 4 |
Squarepoint
New York
|
+$129K |
| 5 |
Goldman Sachs
New York
|
+$91.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$312K |
| 2 |
JP Morgan Chase
New York
|
-$266K |
| 3 |
Renaissance Technologies
New York
|
-$129K |
| 4 |
6CM
683 Capital Management
New York
|
-$98.9K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$74K |
GLMD Hedge Fund Activity: Q1 2020 in Review
28 of the 4,546 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2020, worth a combined $24.5M — down 28% from $34M a quarter earlier.
Fund positioning in GLMD was balanced in Q1 2020: 4 funds opened new positions, 4 closed out, 10 added to existing stakes and 6 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $4.54M. The largest seller was Raymond James & Associates, cutting an estimated $312K.
- 28 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $24.5M of Galmed Pharmaceuticals stock for Q1 2020, down 28% quarter-over-quarter.
- 4 funds opened new Galmed Pharmaceuticals positions in Q1 2020 and 4 closed out, a net change of 0 holders.
- The largest Galmed Pharmaceuticals buyer in Q1 2020 was Vivo Capital, an estimated $4.54M added.
- The largest Galmed Pharmaceuticals seller in Q1 2020 was Raymond James & Associates, an estimated $312K sold.
Based on aggregated 13F filings for Q1 2020.